Can Fite Biopharma Ltd ADR - Asset Resilience Ratio
Can Fite Biopharma Ltd ADR (CANF) has an Asset Resilience Ratio of 31.66% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Can Fite Biopharma Ltd ADR total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Can Fite Biopharma Ltd ADR's Asset Resilience Ratio has changed over time. See shareholders equity of Can Fite Biopharma Ltd ADR for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Can Fite Biopharma Ltd ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Can Fite Biopharma Ltd ADR worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.01 Million | 31.66% |
| Total Liquid Assets | $3.01 Million | 31.66% |
Asset Resilience Insights
- Very High Liquidity: Can Fite Biopharma Ltd ADR maintains exceptional liquid asset reserves at 31.66% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Can Fite Biopharma Ltd ADR Industry Peers by Asset Resilience Ratio
Compare Can Fite Biopharma Ltd ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Can Fite Biopharma Ltd ADR (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Can Fite Biopharma Ltd ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 31.66% | $3.01 Million | $9.51 Million | -1.92pp |
| 2024-12-31 | 33.57% | $3.06 Million | $9.12 Million | -12.92pp |
| 2023-12-31 | 46.49% | $4.64 Million | $9.99 Million | -7.38pp |
| 2022-12-31 | 53.87% | $5.00 Million | $9.28 Million | -18.95pp |
| 2021-12-31 | 72.82% | $14.75 Million | $20.25 Million | +72.04pp |
| 2020-12-31 | 0.79% | $75.00K | $9.52 Million | +0.00pp |
| 2019-12-31 | 0.78% | $64.00K | $8.17 Million | -2.65pp |
| 2018-12-31 | 3.43% | $273.00K | $7.95 Million | -- |
About Can Fite Biopharma Ltd ADR
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase … Read more